🔗 Share this article

As the US proceeds with historic revisions to its vaccine recommendations, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccinations in the global health crisis and has focused upon alleged fatalities after COVID-19 immunization in her recent position at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Immunization Schedule

Agency leaders had intended to announce sweeping revisions to the pediatric vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a major change that would place the US out of alignment with much of the international standard with no evidence for improved outcomes. This reveal has been pushed back until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the gathering. She was just designated interim head of the FDA’s CDER, the fifth individual to run the office this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad solidify control at the agency – and it points to a increased emphasis upon rolling back already-approved vaccines at the FDA.

Høeg has frequently advocated for ending certain childhood shot schedules in the US to become more like Denmark, a nation with comprehensive healthcare and a number of inhabitants about the size of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on immunizations – traditionally the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

The appointee has no obvious experience in medication creation, oversight or management, which has been standard for past heads of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a large organization. She has no expertise in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who headed CBER have had.”

CDER has an enormous workload at the agency, the former commissioner emphasized.

“The public just focuses on the novel medication approvals, but the generic program clears numerous generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and every single one have to be managed,” Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a significant management component to the position, which manages in excess of 5,000 employees. “It’s a huge management job, if you execute it properly,” the former official concluded.

Response and Disputed Programs

In response to inquiries about Høeg’s qualifications and whether this assignment represents increased cooperation among agency officials on vaccines, a press secretary responded that the “questions stem from incorrect presumptions”.

“Her resume aligns with the responsibilities of her position,” the representative said, pointing to the time Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed one-day medication authorization process that reportedly worried her former heads. “By what process are these medications being chosen for this voucher program? Who makes the calls?” Howard questioned. “There’s a lot of secrecy going on at the FDA right now.”

Broadly speaking, he said, “the FDA seems to be moving towards laxer rules of most medications, with the exception of shots.”

Documented Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if concerning, history, Howard said. She released a research paper using unverified public submissions to assess the incidence of myocarditis following COVID-19 immunization. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership encompassed changing regulations for recently developed shots and halting “optional” immunizations, she said following the vote on a podcast. At the FDA, Høeg has allegedly proposed barring adolescent males from obtaining Covid vaccinations.

“She’s an complete true believer who begins with her beliefs and reverse-engineers to fit the data in a extremely deceptive, dishonest way,” Howard said.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow contrarians, {like|